Watch-list Stock News:- Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has market worth of 2.32B along 146.91M outstanding shares. The stock moved 0.25% to $15.84 in recent session. The recent traded volume was 119164 shares. The stock had closed at $15.8 on the previous day.

HALO stock has recorded a weekly performance of 3.95% and monthly performance is -13.76%. Shares have moved -10.33% over the last quarter and changed -20.84% over the recent six months. The shares registered yearly performance at -5.67% and YTD move seen at -22.01%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that Albert Kildani has joined the company in the role of vice president of investor relations and corporate communications.

In this role, Mr. Kildani will develop and execute the company’s investor relations strategy and serve as the primary contact for analysts and the investment community. Additionally, he will oversee all aspects of corporate communications, including public relations and external and internal communications.

Dr. Helen Torley, president and CEO said “I am delighted to have Al join the team”. “Al brings deep experience, both from a company, and from an investor perspective. He will be a valuable addition as we continue to execute our two-pillar strategy, growing ENHANZE® and preparing for the commercialization of PEGPH20.”

Mr. Kildani joins Halozyme from Vital Therapies, Inc., where he served as vice president, investor relations and business development. In this role, he was responsible for the overall strategy and external messaging to institutional investors and performed due diligence on potential business development opportunities. He previously held senior investor relations and corporate communications roles at Hologic, Inc. and Gen-Probe, Inc. Prior to this, he was an analyst with Stark Investments, C.E. Unterberg, Towbin, and Pacific Growth Equities LLC.

In terms of profitability, Halozyme Therapeutics, Inc. has a gross margin of 93.80%, an operating margin of 28.30% and a net profit margin of 23.90%. Return on assets come to 16.50% and return on investment coming to 20.10% while Return on equity come to 38.10%.

Leave a Reply

Your email address will not be published. Required fields are marked *